Article citationsMore>>

Janne, P., Planchard, D., Cheng, Y., Yang, J.C.-H., Yanagitani, N., Kim, S.-W., et al. (2023) PL03.13 Osimertinib with/without Platinum-Based Chemotherapy as First-Line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2). Journal of Thoracic Oncology, 18, S36-S37.
https://doi.org/10.1016/j.jtho.2023.09.009

has been cited by the following article:

• TITLE: Osimertinib Applied in Renal Metastatic Non-Small Cell Lung Cancer with Sensitive EGFR Mutation: Good Response of a Vietnamese Woman

  AUTHORS: Tu Anh Do, Van Thi Nguyen, Hung Khac Tran

  KEYWORDS: Advanced-Stage NSCLC, Renal Metastasis, Third-Generation TKIs, Sensitive EGFR Mutation

  JOURNAL NAME: Open Access Library Journal, Vol.12 No.2, February 17, 2025

  ABSTRACT: Background: Renal metastases from non-small cell lung cancer (NSCLC) are rare, treatment guidelines for renal metastases from NSCLC are unclear, mostly based on clinical case reports. Data on the effectiveness of osimertinib in the group of patients with renal metastatic NSCLC who have epidermal growth factor receptor (EGFR) mutations del19 or L858R is still incomplete. Purpose: In this study, we report a case of the bilateral renal metastatic NSCLC who was treated by the first-line TKIs with osimertinib. Results: This patient had a prolonged response lasting 9 months with third-generation TKI. During treatment, the patient achieved a clinical response and well-tolerated treatment. Conclusion: Renal metastatic NSCLC with TKI-sensitive EGFR mutations revealed a good response to osimertinib.